Our Contribution to Sustainable Patient-Centric Healthcare

We have established collaborative networks with various parties to contribute to the treatment of osteoporosis.

Read an employee comment

Kumamoto and Oita Branch
Yutaro Satake

Launch of an osteoporosis treatment network and related initiatives

Osteoporosis is a serious disease that increases the risk of bone fractures, which may lead to becoming bedridden. However, since there are typically no obvious symptoms until a fracture occurs, it is important to increase the rate of treatment and rate of continuity of treatment. In the region I serve,* there was an urgent need for measures to prevent fractures, and collaboration in various forms (medical-dental collaboration, medical and nursing care collaboration, inter-regional collaboration) was a high priority. Chugai responded by launching an osteoporosis treatment network that involved medical, dental, pharmacist and dietetic associations as well as local government agencies (municipal governments and public health centers). Through this network, we created and applied various tools to facilitate collaboration, including a medical-dental collaboration form, and promoted disease awareness and primary prevention in cooperation with local government agencies.

As a result, the osteoporosis treatment rate in this area increased dramatically between 2017 and 2019. Going forward, we will look to broaden our contribution by further improving the treatment environment and actively disseminating information to other regions, using this region as a model case.

  • *Northern Oita Prefecture Medical Area (City of Nakatsu, Usa and Bungotakada) and Fukuoka Keichiku Medical Area (City of Buzen)

To realize sustainable patient-centric healthcare and create social value, it is important to cooperate with stakeholders, taking into consideration the external conditions affecting the healthcare industry, including rapid progress in science and technology, a changing social structure and environmental degradation.

Chugai will continue to concentrate on innovation, focusing on creating innovative drugs and services. At the same time, we will promote the evolution of every function, from research, development and production to marketing, drug safety and quality and regulatory compliance, to deliver true value for patients and contribute to healthcare itself.

Material Issues

  • Creation of innovative drugs and services
  • Provision of solutions for patients
  • Fair marketing
  • Fair pricing
  • Adverse event management
  • Quality assurance and stable supply of products

Initiatives for Sustainable Patient-Centric Healthcare

  • E-mail
Mesterolon kaufen

Novo Nordisk

buy ECA
Back to top